|
| Press Releases |
|
 |
|
| Monday, October 21, 2024 |
|
|
康哲药业入选2024年度“中国医药上市公司ESG竞争力”系列榜单 |
| 近日，E药经理人联合中国领先的企业社会责任独立咨询机构发布2024年度“中国医药上市公司ESG竞争力”系列榜单，旨在表彰在ESG管理各方面具有标杆作用的中国医药企业。康哲药业凭借在可持续发展、低碳行动方面的不断努力，连续三年入选“中国医药上市公司ESG竞争力TOP20（中盘股）”榜单，并入选首届“中国医药上市公司低碳先锋TOP10”榜单。 more info >> |
|
|
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area |
| China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. more info >> |
|
| Friday, October 18, 2024 |
|
|
康哲药业：芦可替尼乳膏（白癜风）大湾区首批处方落地 |
| 康哲药业控股有限公司（“康哲药业”）欣然宣布，磷酸芦可替尼乳膏（“芦可替尼乳膏”或“产品”）在中山陈星海中西医结合医院、佛山复星禅诚医院、以及东莞松山湖东华医院为符合条件的白癜风患者开出大湾区首批处方。 more info >> |
|
| Tuesday, September 24, 2024 |
|
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
|
康哲药业：磷酸芦可替尼乳膏（白癜风）中国上市许可申请已获受理 |
| 康哲药业控股有限公司（“本公司”，连同其附属公司统称为“本集团”或“康哲药业”）欣然宣布，磷酸芦可替尼乳膏（“芦可替尼乳膏”或“产品”）（白癜风适应症）新药上市许可申请（NDA）已于2024年9月24日获得中国国家药品监督管理局（NMPA）受理。 more info >> |
|
| Friday, August 16, 2024 |
|
|
康哲藥業（00867）發佈2024年中期業績：營業額和利潤環比均穩步提升 |
| 2024年8月15日，康哲藥業發佈2024年中期業績公告，整體營業額和期間利潤環比去年下半年穩步提升。2024年上半年實現營收36.11億元，同比下降21.7%，環比增長6.1%；若全按藥品銷售收入計算營收42.88億元，同比下降22.6%，環比增長8.9%；其中，非國採獨家產品及創新產品合計銷售收入為人民幣24.05億元，佔全按藥品銷售收入計算營業額的56.1%。實現淨利潤9.03億元，同比下降52.8%，環比大幅增長92.8%。 more info >> |
|
|
康哲药业（00867）发布2024年中期业绩：营业额和利润环比均稳步提升 |
| 康哲药业发布2024年中期业绩公告，整体营业额和期间利润环比去年下半年稳步提升。2024年上半年实现营收36.11亿元，同比下降21.7%，环比增长6.1%；若全按药品销售收入计算营收42.88亿元，同比下降22.6%，环比增长8.9%；其中，非国采独家产品及创新产品合计销售收入为人民币24.05亿元，占全按药品销售收入计算营业额的56.1%。实现净利润9.03亿元，同比下降52.8%，环比大幅增长92.8%。 more info >> |
|
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
| On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
| On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 23, 2024 20:42 HKT/SGT
|
|
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
达丰设备服务有限公司 公布2024/25中期业绩
Nov 22, 2024 19:35 HKT/SGT
|
|
|
達豐設備服務有限公司 公佈2024/25中期業績
Nov 22, 2024 19:18 HKT/SGT
|
|
|
透雲生物萊茵衣藻獲國家衛健委新用途許可
Nov 22, 2024 14:42 HKT/SGT
|
|
|
透云生物莱茵衣藻获国家卫健委新用途许可
Nov 22, 2024 14:41 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 12:00: JST
|
|
|
Daeshin MC Co., Ltd.は、産業現場から公共施設まで快適な室内環境を作り出すクリーンソリューションを発表
Nov 22, 2024 12:00: JST
|
|
|
三菱重工、新たな防衛輸送用「機動舟艇」に搭載するウォータージェット推進装置の供給へ
Nov 22, 2024 11:45: JST
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
雅各臣公佈二零二五財年中期業績 持續經營業務溢利飈升44.2%
Nov 22, 2024 10:00 HKT/SGT
|
|
|
アレス・マネジメント、東京オフィス開設でアジア事業を拡充
Nov 22, 2024 09:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
